262 related articles for article (PubMed ID: 26447190)
1. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Matthews GM; Mehdipour P; Cluse LA; Falkenberg KJ; Wang E; Roth M; Santoro F; Vidacs E; Stanley K; House CM; Rusche JR; Vakoc CR; Zuber J; Minucci S; Johnstone RW
Blood; 2015 Nov; 126(21):2392-403. PubMed ID: 26447190
[TBL] [Abstract][Full Text] [Related]
2. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
3. CaMKII exacerbates heart failure progression by activating class I HDACs.
Zhang M; Yang X; Zimmerman RJ; Wang Q; Ross MA; Granger JM; Luczak ED; Bedja D; Jiang H; Feng N
J Mol Cell Cardiol; 2020 Dec; 149():73-81. PubMed ID: 32971072
[TBL] [Abstract][Full Text] [Related]
4. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.
Matsushita H; Scaglioni PP; Bhaumik M; Rego EM; Cai LF; Majid SM; Miyachi H; Kakizuka A; Miller WH; Pandolfi PP
J Exp Med; 2006 Apr; 203(4):821-8. PubMed ID: 16549595
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
6. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
7. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
Long J; Fang WY; Chang L; Gao WH; Shen Y; Jia MY; Zhang YX; Wang Y; Dou HB; Zhang WJ; Zhu J; Liang AB; Li JM; Hu J
Leukemia; 2017 Dec; 31(12):2761-2770. PubMed ID: 28462918
[TBL] [Abstract][Full Text] [Related]
8. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
9. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
10. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.
Heideman MR; Wilting RH; Yanover E; Velds A; de Jong J; Kerkhoven RM; Jacobs H; Wessels LF; Dannenberg JH
Blood; 2013 Mar; 121(11):2038-50. PubMed ID: 23327920
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
Minucci S; Nervi C; Lo Coco F; Pelicci PG
Oncogene; 2001 May; 20(24):3110-5. PubMed ID: 11420727
[TBL] [Abstract][Full Text] [Related]
12. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Wilson AJ; Byun DS; Popova N; Murray LB; L'Italien K; Sowa Y; Arango D; Velcich A; Augenlicht LH; Mariadason JM
J Biol Chem; 2006 May; 281(19):13548-13558. PubMed ID: 16533812
[TBL] [Abstract][Full Text] [Related]
14. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
[TBL] [Abstract][Full Text] [Related]
16. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
18. Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells.
Hennig D; Müller S; Wichmann C; Drube S; Pietschmann K; Pelzl L; Grez M; Bug G; Heinzel T; Krämer OH
Br J Cancer; 2015 Jan; 112(2):329-37. PubMed ID: 25514379
[TBL] [Abstract][Full Text] [Related]
19. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
Zhang X; Chen X; Lin J; Lwin T; Wright G; Moscinski LC; Dalton WS; Seto E; Wright K; Sotomayor E; Tao J
Oncogene; 2012 Jun; 31(24):3002-3008. PubMed ID: 22002311
[TBL] [Abstract][Full Text] [Related]
20. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
